|
Evaluation of EGFR diagnostic testing and treatment patterns in advanced NSCLC patients over time. |
|
|
Employment - PatientsLikeMe; Precision Health AI |
Stock and Other Ownership Interests - PatientsLikeMe; Precision Health AI |
|
|
No Relationships to Disclose |
|
|
Employment - Precision Health AI |
|
|
Employment - FORMA Therapeutics (I) |
Stock and Other Ownership Interests - FORMA Therapeutics (I) |
Consulting or Advisory Role - Foundation Medicine |
|
|
Employment - Precision Health AI |
Leadership - Precision Health AI |
Stock and Other Ownership Interests - Precision Health AI; Transparency Life Sciences |
Consulting or Advisory Role - Transparency Life Sciences |
Research Funding - Precision Health AI |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |